| __timestamp | Bausch Health Companies Inc. | United Therapeutics Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 2026300000 | 381287000 |
| Thursday, January 1, 2015 | 2682700000 | 452612000 |
| Friday, January 1, 2016 | 2810000000 | 316800000 |
| Sunday, January 1, 2017 | 2582000000 | 330100000 |
| Monday, January 1, 2018 | 2473000000 | 265800000 |
| Tuesday, January 1, 2019 | 2554000000 | 336200000 |
| Wednesday, January 1, 2020 | 2367000000 | 423900000 |
| Friday, January 1, 2021 | 2624000000 | 467000000 |
| Saturday, January 1, 2022 | 2625000000 | 487000000 |
| Sunday, January 1, 2023 | 2917000000 | 477100000 |
Cracking the code
In the competitive landscape of the pharmaceutical industry, understanding the financial strategies of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of United Therapeutics Corporation and Bausch Health Companies Inc. over the past decade. From 2014 to 2023, Bausch Health consistently outspent United Therapeutics, with SG&A expenses peaking at approximately $2.9 billion in 2023, marking a 44% increase from 2014. In contrast, United Therapeutics maintained a more conservative approach, with expenses rising by about 25% over the same period, reaching nearly $487 million in 2022. This disparity highlights differing strategic priorities, with Bausch Health potentially focusing on aggressive market expansion and United Therapeutics emphasizing cost efficiency. Such insights are invaluable for investors and industry analysts seeking to understand the financial health and strategic direction of these pharmaceutical giants.
Gilead Sciences, Inc. vs United Therapeutics Corporation: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of United Therapeutics Corporation and Genmab A/S
United Therapeutics Corporation and Bio-Techne Corporation: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: United Therapeutics Corporation vs Lantheus Holdings, Inc.
SG&A Efficiency Analysis: Comparing United Therapeutics Corporation and Catalyst Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for United Therapeutics Corporation and Bausch Health Companies Inc.
United Therapeutics Corporation vs Vericel Corporation: SG&A Expense Trends
United Therapeutics Corporation vs Xencor, Inc.: SG&A Expense Trends
CRISPR Therapeutics AG and Bausch Health Companies Inc.: SG&A Spending Patterns Compared
Bausch Health Companies Inc. vs Amicus Therapeutics, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Bausch Health Companies Inc. and Xencor, Inc.
Bausch Health Companies Inc. or Evotec SE: Who Manages SG&A Costs Better?